Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale’s deal flow keeps a healthy beat

HEALTHAnalyst Comment29.10.2026 klo 09.05
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health announced two new proteomics service agreements, each valued at 1 MUSD (~0.9 MEUR), following a major contract in September and several smaller partnerships over the summer and fall.
  • The agreements involve analyzing 10,000 UK Biobank blood samples for neurodegenerative diseases, extending the company's recent successes in proteomics.
  • The newly announced contracts are expected to be recognized as revenue primarily in the current financial year, with a lower project margin compared to Nightingale's own NMR technology.
  • Nightingale guides for revenue of at least 10.0 MEUR in the current financial year, with the new agreements providing a boost to short-term figures, while long-term value creation focuses on scaling clinical partnerships with recurring revenue.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 10/29/2026 at 7:45 am EET.

On Wednesday, Nightingale Health announced two proteomics service agreements (1, 2), each valued at 1 MUSD (~0.9 MEUR). The news follows the major proteomics contract signed in September and several smaller partnerships announced over the summer and fall. These one-off projects put upward pressure on our forecasts for the current financial year, and we will update our model accordingly shortly.

New proteomics projects in quick succession

Under both agreements, Nightingale will analyze 10,000 UK Biobank blood samples using a test panel from US-based Alamar Biosciences focused on neurodegenerative diseases. One of the clients is Alzheimer’s Research UK and the other LifeArc. In late September, the company announced a proteomics contract worth 6.5 MUSD (~5.8 MEUR) with the Michael J. Fox Foundation. That project will analyze 60,000 samples using the same technology. The new agreements thus extend the company’s run of successes in proteomics. We estimate that the newly announced contracts will be recognized as revenue primarily in the current financial year (2026/2027). We have previously estimated that the project margin on analyses using a partner’s technology is likely lower than on Nightingale’s own NMR technology. The relative earnings impact of these projects is therefore smaller than in the company’s own NMR-based business. Beyond proteomics, Nightingale has announced numerous other contracts and partnerships over the summer and fall. We estimate these to be mainly small individually, but together they support the company’s growth. The precise value of this deal flow will only become clear in future reports.

Research revenue provides important support for the coming years

Nightingale guides for revenue of at least 10.0 MEUR in the current financial year. Before the new agreements, our revenue forecast for the current financial year was 12.0 MEUR. The two additional contracts, worth ~0.9 MEUR each, thus provide a welcome boost to the company’s short-term figures and reduce the risk in our current-year forecasts. Although individual research projects bring the company important cash flow and strengthen its position in medical research, they are project-based and non-recurring by nature. From the perspective of long-term value creation, our main focus therefore remains on how the company’s own clinical partnerships with recurring revenue (such as Pathology Asia and Boston Heart) scale up in the coming years.

Login required

This content is only available for logged in users

Create account

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures08.10.

202627e28e
Revenue5.512.012.0
growth-%17.2 %118.1 %-0.4 %
EBIT (adj.)-18.8-14.1-13.5
EBIT-% (adj.)-341.8 %-117.3 %-112.7 %
EPS (adj.)-0.30-0.23-0.22
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

There was just a segment of a few minutes on this on the 10 o’clock news! Nightingale wasn’t mentioned by name, but it’s great if this helps...
11/11/2026, 8:17 PM
by Yariskuski
7
mtvuutiset.fi – 11 Nov 26 Työttömien terveystarkastuksiin uusi verikoe: Sairastumisriskejä arvioidaan... Työttömien terveystarkastuksissa otetaan...
11/11/2026, 9:39 AM
by Pertti
13
Inderes Nightingale Healthin sairastumisriskien tunnistus saataville Alankomaissa... Nightingale Health Oyj | Lehdistötiedote | 10.11.2026 klo...
11/10/2026, 7:03 AM
by Pertti
21
Well, well. It could be that these continuous little breadcrumbs of news are (no longer so weak) signals of an impending tsunami. And these ...
11/6/2026, 9:50 AM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
9
Inderes Nightingale Healthin sairastumisriskien tunnistus osaksi lontoolaisen Barnes... Nightingale Health Oyj | Lehdistötiedote | 06.11.2026...
11/6/2026, 9:02 AM
by Pertti
17
NGH doesn’t have clinical validation in Europe either for all the parameters they advertise for research use. Different audiences, different...
11/6/2026, 7:53 AM
by omegaalpha
0
As I understand it, one LDT approval covers a bundle from a total set of different blood biomarkers/values, of which there are about 250 in ...
11/6/2026, 6:08 AM
by Pertti
2